Drug intelligence / Profile preview

NAL8812

Development stage: Preclinical
Lead developer: Nal Pharmaceuticals
Modality: Small Molecules
Administration: Transdermal

Overview

NAL8812 is a transdermal patch formulation of donepezil, an acetylcholinesterase inhibitor, being developed by NAL Pharmaceutical Group for the treatment of Alzheimer's disease. The patch is designed for 3-day (twice-weekly) administration, utilizing NAL's proprietary transdermal delivery technology to provide sustained release of the drug. By inhibiting acetylcholinesterase, it increases the concentration of acetylcholine in the brain, which is intended to improve cognitive function in patients with Alzheimer's. The transdermal route aims to reduce gastrointestinal side effects and improve patient compliance compared to oral formulations.

Other names: Donepezil 3-Day PatchDonepezil3-Day PatchDonepezil-3-Day Patch

Targets

Acetylcholinesterase

Beyond the preview

Go deeper on NAL8812.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAL8812.

Explore the full profile